PUBLISHER: IMARC | PRODUCT CODE: 1702038
PUBLISHER: IMARC | PRODUCT CODE: 1702038
The global anti-infectives market size reached USD 138.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 180.0 Billion by 2033, exhibiting a growth rate (CAGR) of 2.93% during 2025-2033.
Anti-infectives are medicines that act against infections, either by inhibiting the spread or killing the infectious agent outright. These medicines include antibiotics, antivirals, antifungals, antimalarials, anthelmintics, and antiprotozoals. They are generally administered through oral, parenteral, and topical routes. They are widely used to treat minor infectious diseases, including pneumonia and tuberculosis. Apart from this, anti-infectives are also utilized during routine procedures and surgeries, such as cesarian section and joint replacement, which are associated with a high risk of severe infection.
The global anti-infectives market is primarily driven by rising incidences of infectious diseases across the globe. Anti-Infinitives are used to treat infections, including viruses, bacteria, parasites, and fungi. Additionally, the development of novel drugs that are formulated using different strategies, such as natural products, quorum sensing inhibitors, biofilm disruptors, gallium-based drugs, cyclodextrin inhibitors, and light-based antimicrobials, are providing an impetus to the market growth. In line with this, the latest innovations in drug discovery procedures, such as stem cells and organ-on-chip (OOC) technologies, to enhance drug trial processes are creating a positive outlook for the market. Furthermore, the increasing product adoption due to the advent of the COVID-19 disease and induced infections, such as aspergillosis, invasive candidiasis, and mucormycosis, is strengthening the growth of the market. Besides this, the increasing number of new anti-infective drugs being approved by the regulatory authorities is acting as another growth-inducing factor. Moreover, the implementation of favorable government policies, rising investments in developing new and innovative drugs, increasing awareness among individuals about infectious diseases, and rapidly improving healthcare infrastructure are anticipated to impel the growth of the market in the coming years.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Cipla Health Ltd. (Cipla Limited), F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Johnson & Johnson, Lupin Limited, Sandoz AG (Novartis AG) and Sun Pharmaceutical Industries Limited.